Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Bailey & Dalrymple

This article was originally published in The Tan Sheet

Executive Summary

Bailey & Dalrymple: Former Merck and American Cyanamid government relations execs William Bailey and Dack Dalrymple establish Washington, D.C. government relations, FDA regulatory affairs and public relations consulting firm. Bailey previously managed government relations for the Nonprescription Drug Manufacturers Association and founded the Bailey & Robinson unit of Ketchum Public Relations. Dalrymple, who also worked with Ketchum, served on Capitol Hill as majority counsel to the House Commerce/Health Subcommittee and legislative assistant to Rep. Paul Rogers (D-Fla.) before joining Cyanamid and Lederle. Former Bailey & Robinson Legislative and Regulatory Counsel Gregory Fisher also joins the firm as VP. Fisher's work experience includes positions with FDA, Royer & Shacknai and NDMA...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS086477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel